The 507 ESCC patients were divided into two groups: patients with copy number amplification of FAM84B (named as FAM84BAmp, ≥ 0.5) and patients without copy number amplification of FAM84B (named as FAM84Bnon-Amp,< 0.5). Here, LRATD2 is linked to esophageal squamous cell carcinoma.